AMDL Launches Major Effort for a Partner for Its Novel Combination Immunogene Therapy for Cancer
May 03 2004 - 8:01AM
PR Newswire (US)
AMDL Launches Major Effort for a Partner for Its Novel Combination
Immunogene Therapy for Cancer TUSTIN, Calif., May 3
/PRNewswire-FirstCall/ -- AMDL, Inc. , developer and marketer of
tests for the early detection of cancer and other serious diseases,
today announced that it has launched a major effort to seek a
strategic partner for clinical trials, and eventual marketing, of
its unique Combination Immunogene Therapy (CIT). The therapy uses
two genes in combination to build the body's immune system and to
destroy cancer cells. The GM-CSF gene alters the tumor to activate
tumor-specific T-cells within the immune system, while the B7-2
gene enters the tumor to stimulate larger and stronger T-cells to
fight the cancer. This is a variation of the traditional concept of
gene therapy, which seeks to replace damaged or abnormal genes with
healthy ones. Replacing defective genes in cancer cells has proven
impractical because of the number of genes involved. CIT has
undergone successful Phase I clinical trials in skin and brain
cancer patients and was shown to be 100 percent effective in a
humanized mouse model at the University of Alberta, Canada.
Publications that have reported on this therapy include "Human Gene
Therapy" and "Neurosurgery". "Large pharmaceutical companies are
anxious to find novel treatments in the multi-billion dollar global
cancer market. Combination Immunogene Therapy is a unique approach
to this deadly disease," said Gary Dreher, AMDL President and CEO.
"AMDL is a theranostics company, meaning we are involved both in
the treatment of the disease, with our CIT therapy, and in the
detection, with our DR-70(R) cancer blood test kit. The Company
currently is supplying information requested by the U.S. Food and
Drug Administration as part of the process in seeking clearance to
market the DR-70(R) test," Mr. Dreher said. About AMDL AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, is a theranostics
company, involved in the detection and treatment of the same
disease, cancer. AMDL is the inventor, developer and worldwide
marketer through exclusive distribution agreements of the DR-70(R)
non-invasive cancer blood test, which has demonstrated its ability
to detect the presence in humans of up to 13 cancers 84 percent of
the time overall. In a study published in the Journal of
Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect
at least 13 different types of cancer (lung, breast, stomach,
liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic,
thyroid, malignant lymphoma, pancreatic) although the sample size
for 9 of the cancers was not statistically significant. Clinical
trials of DR-70(R) have been conducted in Canada, China, Germany,
Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a
single tube of blood, eliminating the need for costly, multiple
tests. AMDL also owns a combination immunogene therapy technology
that is a possible treatment for those already diagnosed with
cancer and could eventually be used as a vaccine to protect
patients known to be at risk because of a family history for
certain types of cancer. The combination therapy both builds the
body's immune system and destroys cancer cells. More information
about AMDL and its additional products can be obtained at
http://www.amdlcorporate.com/. Forward-Looking Statements
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's partners that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. The actual results may differ
materially from those contained in this press release. The Company
disclaims any obligation to update any statements in this press
release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdlcorporate.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024